Publishers
Science & Tech • Business • Investing & Finance
How Applicant Tracking Systems Fit into a Comprehensive HR Tech Stack
February 27, 2025

Hiring the right talent is one of the most critical functions of any business. But as the hiring process becomes more complex, companies need technology to help them manage every stage of recruitment efficiently. This is where an applicant tracking system comes in. By automating and streamlining tasks like job postings, resume screening, and interview scheduling, an applicant tracking system helps HR teams work more effectively.

However, hiring is just one piece of the larger HR puzzle. A company’s HR team is responsible for onboarding, payroll, performance management, benefits administration, and compliance. To handle all of these functions seamlessly, businesses rely on HR management software to integrate their hiring systems with broader employee management tools.

A well-structured HR tech stack ensures that each component—recruiting, employee management, payroll, and more—works together without inefficiencies or data silos. In this article, we’ll explore how an applicant tracking system fits into a comprehensive HR tech stack, why integration is essential, and what businesses should consider when building their HR technology ecosystem.

The role of an applicant tracking system in HR technology

An applicant tracking system is designed to improve efficiency in recruitment. It automates time-consuming tasks, tracks candidate progress, and ensures that hiring managers and HR professionals can collaborate effectively. But its true power lies in how it connects with the other tools in an organization’s HR tech stack.

When an applicant tracking system integrates with HR management software and other HR tools, companies gain a more seamless way to manage employees from their first interaction with the company through every stage of their career. Without these integrations, HR teams may face redundant data entry, disjointed workflows, and missed opportunities for efficiency.

How an applicant tracking system fits into a comprehensive HR tech stack

A complete HR tech stack consists of multiple interconnected tools that support hiring, employee management, and workforce planning. Here’s how an applicant tracking system plays a crucial role within this ecosystem.

Connecting recruitment with onboarding

Once a candidate accepts a job offer, the next step is a smooth transition into the company. A strong HR tech stack ensures that new hire data from an applicant tracking system automatically transfers to onboarding software, eliminating the need for manual data entry.

  • Seamless data transfer: When recruitment and onboarding systems are integrated, new hires don’t have to re-enter personal information, reducing errors and administrative work.
  • Automated onboarding workflows: Digital offer letters, tax forms, training schedules, and company handbooks can be delivered automatically, making the onboarding process more efficient.

Integration with HR management software

An applicant tracking system should be part of a broader HR system that helps businesses manage employees long after they are hired. By integrating with HR management software, companies can ensure that data flows seamlessly between hiring, payroll, benefits administration, and compliance functions.

  • Centralized employee records: Hiring data, including resumes, interview feedback, and employment history, can be stored in HR management software for easy reference.
  • Workforce planning and analytics: By connecting hiring data with broader HR insights, organizations can make more informed decisions about staffing needs and talent development.

Streamlining payroll and benefits administration

An applicant tracking system also plays a role in payroll and benefits by ensuring that accurate information about new hires is transferred to payroll systems.

  • Accurate salary and tax information: Compensation details from job offers can be directly imported into payroll systems, reducing manual errors.
  • Efficient benefits enrollment: Employees can be automatically enrolled in health insurance, retirement plans, and other benefits without redundant paperwork.

Ensuring compliance and reporting

HR teams must comply with various employment laws, diversity hiring goals, and data privacy regulations. An applicant tracking system helps maintain accurate records and supports compliance efforts.

  • Diversity and equal employment tracking: Many applicant tracking systems include tools to monitor hiring trends and ensure compliance with equal employment opportunity regulations.
  • Audit-ready documentation: A centralized record of hiring decisions, interview feedback, and candidate communications helps businesses stay compliant with labor laws.

Enhancing collaboration with communication tools

Hiring is a team effort that involves recruiters, hiring managers, and executives. An applicant tracking system improves collaboration by integrating with email, messaging platforms, and scheduling tools.

  • Automated interview scheduling: An applicant tracking system can sync with calendar apps to suggest available interview times for hiring teams.
  • Real-time feedback and communication: Recruiters and managers can leave comments on candidate profiles, track interview progress, and make hiring decisions without relying on email chains.

Leveraging AI and data-driven insights

The best applicant tracking systems do more than just track candidates—they provide insights that help companies improve their hiring strategies.

  • Identifying hiring bottlenecks: HR teams can analyze where candidates drop out of the hiring process and adjust their approach to reduce delays.
  • Improving job descriptions: AI-powered tools can assess job postings and suggest changes to attract better-qualified applicants.

Choosing the right applicant tracking system for your HR tech stack

Not all applicant tracking systems are created equal. To ensure that an applicant tracking system fits well within an existing HR tech stack, companies should consider:

  • Integration capabilities: Does the applicant tracking system connect with HR management software, payroll, and onboarding tools?
  • User experience: Is the interface intuitive for both recruiters and candidates?
  • Scalability: Can the system handle increased hiring needs as the company grows?
  • Automation and AI features: Does it reduce manual tasks and provide useful insights?
  • Security and compliance: Does it include features to help with legal compliance and data security?

The future of applicant tracking system integration in HR technology

HR technology is evolving, and the role of an applicant tracking system will continue to expand. Companies can expect to see:

  • AI-driven candidate matching: More applicant tracking systems will use AI to pair candidates with jobs based on skills and experience.
  • Automated chatbots for candidate engagement: AI-powered chatbots will assist with answering applicant questions and scheduling interviews.
  • Deeper integration with workforce planning: Hiring data will be used to predict future staffing needs and skill gaps.

Conclusion

An applicant tracking system is a fundamental part of a company’s HR tech stack, but its true value comes from how well it integrates with other HR tools. By connecting hiring processes with HR management software, payroll, onboarding, and analytics, companies can create a seamless experience for both candidates and employees.

For businesses looking to build a high-performing HR tech stack, selecting an applicant tracking system that integrates smoothly with existing tools is essential. A well-connected system not only streamlines hiring but also supports long-term workforce planning, compliance, and employee engagement—ensuring that HR teams can focus on what matters most: finding and retaining top talent.

community logo
Join the Publishers Community
To read more articles like this, sign up and join my community today
0
What else you may like…
Posts
Articles
How AI Is Transforming the Waste Management Business for Smarter Routing

The waste management industry is undergoing a dramatic shift thanks to artificial intelligence (AI). From optimizing trash collection routes to predicting maintenance needs for garbage trucks, AI is helping companies reduce operational costs, improve sustainability, and better serve customers. With the rapid advancement of machine learning, computer vision, and IoT (Internet of Things) technologies, AI-driven systems are no longer futuristic—they're being implemented right now in waste operations around the world.

Waste management business leaders are especially benefiting from smarter routing systems made possible by AI. Traditionally, garbage and recycling trucks followed static schedules and routes, often resulting in underfilled bins being collected or full bins being missed. Now, AI-powered systems use real-time data from sensors installed in containers, along with GPS and traffic data, to create the most efficient collection routes possible. These smart-routing algorithms not only reduce ...

post photo preview
Therapist Abuse: Know Your Rights and Why You Need a Lawyer on Your Side

Therapists play a crucial role in supporting mental health and emotional well-being. When working with a therapist, patients entrust them with their most personal experiences and vulnerabilities. Unfortunately, not all therapeutic relationships are safe or ethical. Therapist abuse can cause serious harm, and victims need to understand their rights and legal options. This article will explore what therapist abuse entails, the signs to watch for, and why having a lawyer can make all the difference in seeking justice and protection.
What Is Therapist Abuse?
Therapist abuse refers to any unethical or harmful behavior by a mental health professional toward a patient. Abuse can take many forms, including emotional, physical, sexual, or financial exploitation. Because of the inherent power imbalance in a therapist-patient relationship, abuse can be particularly damaging and complex.
Common Types of Therapist Abuse
Sexual misconduct: This includes any unwanted sexual advances, touching, or inappropriate comments made by a therapist.

Emotional manipulation: Therapists may ...

post photo preview

Video has quickly become one of the most powerful content medium in a business’s marketing toolkit. Whether you’re launching a new product, hosting a live event, or creating brand content, video helps you connect with your audience in ways no other medium can. But there’s a catch: to make great video, you need a great videographer.

And here’s where many new clients go wrong.

Hiring a videographer sounds simple—ask around, check a portfolio, sign a contract, right? Not quite. There are several critical decisions and assumptions that can turn what should be an amazing project into a frustrating (and expensive) disappointment.

In this guide, we’ll cover the top 5 mistakes clients make when hiring a videographer—and how you can avoid them to ensure a smooth, successful, and impactful production.

Mistake #1: Not Defining the Project Goals Clearly

The Problem:
A surprising number of clients approach videographers with vague objectives like “We need a cool video” or “Just make something that looks good.” While the creative freedom might sound appealing, it often leads to misaligned expectations and ...

post photo preview
Biotech Startups Secure Billions for Groundbreaking Autoimmune Therapies Amid Booming Market

In an impressive show of confidence for novel treatment approaches, biotechnology startups focusing on autoimmune diseases have secured massive funding throughout 2025, signaling robust investor enthusiasm for next-generation therapies that could potentially reset immune system function rather than simply managing symptoms. This funding surge comes as the global autoimmune disease therapeutics market demonstrates strong growth projections, with increasing prevalence of conditions like rheumatoid arthritis, lupus, and multiple sclerosis driving unprecedented investment in innovative solutions.

Major Funding Rounds Demonstrate Investor Confidence

The first half of 2025 witnessed remarkable venture capital activity in the autoimmune space, with several startups securing substantial financing to advance their clinical programs. The robust funding environment reflects what industry observers describe as renewed investor confidence for companies with compelling science and clear patient benefits following a market correction in 2022-2023.

Table: Select Autoimmune Therapy Funding Rounds (2024-2025)

Company

Amount Raised

Date

Therapeutic Approach

Primary Indication

Abcuro

$200M

February 2025

Anti-KLRG1 monoclonal antibody

Inclusion body myositis (IBM)

Timberlyne Therapeutics

$180M

January 2025

Anti-CD38 monoclonal antibody

Multiple autoimmune diseases

SetPoint Medical

$140M

August 2025

Vagal nerve modulation device

Rheumatoid arthritis

GlycoEra

$130M

May 2025

IgG4-targeted degrader platform

Multiple autoimmune diseases

Dualitas Therapeutics

$65M

2025

Bispecific antibodies platform

Multiple autoimmune diseases

These financings represent just a portion of the $1.1 billion that autoimmune-focused ventures secured across 17 deals in the first half of 2025 alone, matching the volume and value seen in the previous six-month period. The substantial investments are flowing to companies developing everything from precision extracellular protein degraders to bispecific antibodies and innovative neuroimmunomodulation devices.

Autoimmune Therapeutics Market Demonstrates Strong Growth Trajectory

This startup funding boom occurs against the backdrop of a rapidly expanding global marketplace for autoimmune treatments. The Autoimmune Disease Therapeutics Market was valued at USD 76.33 billion in 2024 and is expected to reach USD 117.33 billion by 2032, growing at a CAGR of 5.52% from 2025-2032. This growth is primarily driven by the rising global prevalence of autoimmune disorders, which have seen incidence increase by 19.1% annually according to National Institutes of Health data. Additional factors fueling market expansion include advancements in biologic therapies, growing R&D investments, and improved diagnostic capabilities enabling earlier treatment intervention.

Strategic Partnerships and M&A Activity Reshape Landscape

Beyond straight equity financing, the autoimmune space has witnessed significant partnership deals and mergers in 2025, demonstrating how established pharmaceutical companies are seeking to supplement their pipelines with innovative external assets.

In the first half of 2025, 21 autoimmune R&D partnerships were completed with a total disclosed value of $10.7 billion – a 34% increase over the previous six-month period despite slightly fewer deals. This boosted the average deal size from $330 million to $510 million, though upfront payments declined significantly, indicating a shift toward back-loaded deal structures with greater reliance on milestone payments.

Notable partnerships included AstraZeneca's discovery-stage deal with Syneron Bio valued at up to $3.4 billion to develop macrocyclic peptide therapies for autoimmune diseases, and Earendil Labs' agreement with Sanofi on a bispecific antibody platform for inflammatory bowel disease, potentially worth $1.7 billion in milestones.

On the mergers and acquisitions front, activity included Alumis's acquisition of Acelyrin in a $737 million all-stock transaction to expand its pipeline in thyroid and neurologic autoimmune conditions, among other strategic combinations.

Novel Therapeutic Approaches Attracting Significant Interest

The diversity of mechanisms receiving funding underscores the breadth of scientific innovation in the autoimmune space. Unlike traditional approaches that broadly suppress the immune system, these novel therapies aim for more precise intervention in disease pathways.

Neuroimmune modulation represents a particularly innovative approach, exemplified by SetPoint Medical's recently funded vagus nerve stimulation technology. "The SetPoint System represents a first-of-its-kind approach to treating rheumatoid arthritis by utilizing neuroimmune modulation," noted company representatives following their $140 million financing round. This technology aims to modulate the body's inflammatory response through targeted electrical stimulation of the vagus nerve, offering a potentially revolutionary non-pharmacological intervention for autoimmune conditions.

Other promising approaches include CAR T-cell therapies for autoimmune conditions, which companies like Bristol Myers Squibb are advancing for lupus and multiple sclerosis , and bispecific antibodies that can simultaneously target multiple disease pathways. Dualitas Therapeutics, which launched with $65 million in Series A funding, is leveraging its DualScreen platform technology to identify promising bispecific combinations for autoimmune treatment.

Market Outlook and Future Directions

The confluence of strong venture funding, strategic partnerships, and market growth projections paints a promising picture for the future of autoimmune disease treatment. The Asia-Pacific region is expected to witness the fastest growth, with a projected CAGR of 7.25% from 2024 to 2032, driven by rising autoimmune disease incidence and improving healthcare access in emerging economies.

As Margaret Keegan, CEO of Precision Medicine Group, observed regarding the evolving biotech funding environment: "A biotech sponsor told me they felt our team cared about their timelines and patient population as much as they did – that's the difference an integrated and genuinely invested partner can make". This shift from transactional relationships to strategic partnerships appears to be paying dividends across the autoimmune therapeutic landscape.

With the global autoimmune disease therapeutics market projected to expand by over $40 billion in the coming years  and venture funding remaining robust for promising science, patients suffering from autoimmune conditions can anticipate a continuing stream of innovative treatments reaching clinical development and eventually the marketplace. The significant investments in novel approaches throughout 2025 suggest the industry is moving beyond traditional immunosuppressive strategies toward more targeted, potentially curative interventions that could dramatically improve patient outcomes in the years ahead.

Read full Article
post photo preview
Biotech Startups Secure Billions for Groundbreaking Autoimmune Therapies Amid Booming Market

In an impressive show of confidence for novel treatment approaches, biotechnology startups focusing on autoimmune diseases have secured massive funding throughout 2025, signaling robust investor enthusiasm for next-generation therapies that could potentially reset immune system function rather than simply managing symptoms. This funding surge comes as the global autoimmune disease therapeutics market demonstrates strong growth projections, with increasing prevalence of conditions like rheumatoid arthritis, lupus, and multiple sclerosis driving unprecedented investment in innovative solutions.

Major Funding Rounds Demonstrate Investor Confidence

The first half of 2025 witnessed remarkable venture capital activity in the autoimmune space, with several startups securing substantial financing to advance their clinical programs. The robust funding environment reflects what industry observers describe as renewed investor confidence for companies with compelling science and clear patient benefits following a market correction in 2022-2023.

Table: Select Autoimmune Therapy Funding Rounds (2024-2025)

Company

Amount Raised

Date

Therapeutic Approach

Primary Indication

Abcuro

$200M

February 2025

Anti-KLRG1 monoclonal antibody

Inclusion body myositis (IBM)

Timberlyne Therapeutics

$180M

January 2025

Anti-CD38 monoclonal antibody

Multiple autoimmune diseases

SetPoint Medical

$140M

August 2025

Vagal nerve modulation device

Rheumatoid arthritis

GlycoEra

$130M

May 2025

IgG4-targeted degrader platform

Multiple autoimmune diseases

Dualitas Therapeutics

$65M

2025

Bispecific antibodies platform

Multiple autoimmune diseases

These financings represent just a portion of the $1.1 billion that autoimmune-focused ventures secured across 17 deals in the first half of 2025 alone, matching the volume and value seen in the previous six-month period. The substantial investments are flowing to companies developing everything from precision extracellular protein degraders to bispecific antibodies and innovative neuroimmunomodulation devices.

Autoimmune Therapeutics Market Demonstrates Strong Growth Trajectory

This startup funding boom occurs against the backdrop of a rapidly expanding global marketplace for autoimmune treatments. The Autoimmune Disease Therapeutics Market was valued at USD 76.33 billion in 2024 and is expected to reach USD 117.33 billion by 2032, growing at a CAGR of 5.52% from 2025-2032. This growth is primarily driven by the rising global prevalence of autoimmune disorders, which have seen incidence increase by 19.1% annually according to National Institutes of Health data. Additional factors fueling market expansion include advancements in biologic therapies, growing R&D investments, and improved diagnostic capabilities enabling earlier treatment intervention.

Strategic Partnerships and M&A Activity Reshape Landscape

Beyond straight equity financing, the autoimmune space has witnessed significant partnership deals and mergers in 2025, demonstrating how established pharmaceutical companies are seeking to supplement their pipelines with innovative external assets.

In the first half of 2025, 21 autoimmune R&D partnerships were completed with a total disclosed value of $10.7 billion – a 34% increase over the previous six-month period despite slightly fewer deals. This boosted the average deal size from $330 million to $510 million, though upfront payments declined significantly, indicating a shift toward back-loaded deal structures with greater reliance on milestone payments.

Notable partnerships included AstraZeneca's discovery-stage deal with Syneron Bio valued at up to $3.4 billion to develop macrocyclic peptide therapies for autoimmune diseases, and Earendil Labs' agreement with Sanofi on a bispecific antibody platform for inflammatory bowel disease, potentially worth $1.7 billion in milestones.

On the mergers and acquisitions front, activity included Alumis's acquisition of Acelyrin in a $737 million all-stock transaction to expand its pipeline in thyroid and neurologic autoimmune conditions, among other strategic combinations.

Novel Therapeutic Approaches Attracting Significant Interest

The diversity of mechanisms receiving funding underscores the breadth of scientific innovation in the autoimmune space. Unlike traditional approaches that broadly suppress the immune system, these novel therapies aim for more precise intervention in disease pathways.

Neuroimmune modulation represents a particularly innovative approach, exemplified by SetPoint Medical's recently funded vagus nerve stimulation technology. "The SetPoint System represents a first-of-its-kind approach to treating rheumatoid arthritis by utilizing neuroimmune modulation," noted company representatives following their $140 million financing round. This technology aims to modulate the body's inflammatory response through targeted electrical stimulation of the vagus nerve, offering a potentially revolutionary non-pharmacological intervention for autoimmune conditions.

Other promising approaches include CAR T-cell therapies for autoimmune conditions, which companies like Bristol Myers Squibb are advancing for lupus and multiple sclerosis , and bispecific antibodies that can simultaneously target multiple disease pathways. Dualitas Therapeutics, which launched with $65 million in Series A funding, is leveraging its DualScreen platform technology to identify promising bispecific combinations for autoimmune treatment.

Market Outlook and Future Directions

The confluence of strong venture funding, strategic partnerships, and market growth projections paints a promising picture for the future of autoimmune disease treatment. The Asia-Pacific region is expected to witness the fastest growth, with a projected CAGR of 7.25% from 2024 to 2032, driven by rising autoimmune disease incidence and improving healthcare access in emerging economies.

As Margaret Keegan, CEO of Precision Medicine Group, observed regarding the evolving biotech funding environment: "A biotech sponsor told me they felt our team cared about their timelines and patient population as much as they did – that's the difference an integrated and genuinely invested partner can make". This shift from transactional relationships to strategic partnerships appears to be paying dividends across the autoimmune therapeutic landscape.

With the global autoimmune disease therapeutics market projected to expand by over $40 billion in the coming years  and venture funding remaining robust for promising science, patients suffering from autoimmune conditions can anticipate a continuing stream of innovative treatments reaching clinical development and eventually the marketplace. The significant investments in novel approaches throughout 2025 suggest the industry is moving beyond traditional immunosuppressive strategies toward more targeted, potentially curative interventions that could dramatically improve patient outcomes in the years ahead.

Read full Article
post photo preview
Daniel J. Cullen: Building Resilient Communities in Wisconsin

Leadership Beyond the Workplace

For Daniel J. Cullen, leadership doesn’t stop at the doors of Precision Metal Fab Inc. While his role as Director requires him to make strategic decisions for long-term business success, he believes his true impact comes from investing in the community around him.

“Strong businesses and strong communities depend on each other,” Cullen explains. “You can’t have one without the other.”

Coaching as Community Building

Through his work as a youth basketball coach in Waukesha and a boxing instructor at both Haley Cullen Wellness and Rock Steady Boxing in Janesville, Cullen uses sports as a way to teach resilience, discipline, and teamwork. These lessons extend beyond athletics, preparing young people and adults alike to contribute positively to society.

Faith and Service as Anchors

Cullen’s commitment to St. Anthony’s on the Lake Family Program reflects his belief that faith and service go hand in hand with civic responsibility. By helping organize family-centered initiatives, he strengthens the bonds that hold communities together.

His participation in the Tim Cullen Institute further highlights his dedication to shaping future civic leaders through mentorship and public engagement.

Resilience Through Responsibility

Cullen believes that resilient communities are built on shared responsibility — from business leaders creating jobs, to coaches mentoring youth, to volunteers supporting families. His own example demonstrates how individuals can strengthen communities by simply showing up and leading with integrity.

Conclusion

For Daniel J. Cullen, building resilient communities means blending professional expertise with personal commitment. By leading in business, coaching in sports, and serving in faith-based and civic programs, he embodies a model of leadership rooted in responsibility.

His story illustrates that resilience isn’t built overnight — it’s created day by day, through service, mentorship, and a commitment to making Wisconsin stronger.

 

Read full Article
Available on mobile and TV devices
google store google store app store app store
google store google store app tv store app tv store amazon store amazon store roku store roku store
Powered by Locals